GEXVal CEO Speaks at University of Tokyo Hospital Drug Discovery Training Program

株式會社GEXVal
November 21, 2025

GEXVal CEO Delivers a Lecture at University of Tokyo Hospital TR/Academia Drug Discovery Training Program 2025

GEXVal Inc. (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) announces that President and CEO Dr. Juran Kato was invited to speak at the “TR・Academia Training Program 2025” hosted by The University of Tokyo Hospital, where she delivered a lecture titled "How to Deliver Medicines to Patients with Rare Diseases."

This Program aims to develop professionals who can bridge academic research, drug discovery, clinical trials, and market implementation, addressing critical challenges in Japanese healthcare including drug lag, drug loss, and declining drug discovery capabilities.

In her lecture, Dr. Kato shared insights from clinical-stage biopharma venture operations, covering global collaborations with pharmaceutical companies, patient advocacy groups, and academia. Topics included Japan's drug lag and loss landscape, rare disease development strategies, the value of drug repurposing, and practical aspects of conducting clinical trials in Australia.

The lecture was well-received by participants, who noted the "multifaceted perspective was extremely valuable" and appreciated the opportunity to "deeply examine challenges in Japanese pharmaceutical circumstances and potential solutions." Participant feedback showed strong satisfaction, with all respondents indicating they were satisfied and 80% expressing high satisfaction with the content.

Dr. Toshitake Kobayashi, Senior Director of GEXVal's CMC will also present at the program on December 11th, speaking on "Manufacturing in Drug Discovery: The Art and Science."

**Presentation Details**

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

有關本事宜請諮詢:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com